This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamanaka, R. Articles by Tanaka, R. Search for Related Content PubMed PubMed Citation Articles by Yamanaka, R. Articles by Tanaka, R.

Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial

Authors' Affiliations: ¹ Department of Neurosurgery, Brain Research Institute and ² Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan

Requests for reprints: Ryuya Yamanaka, Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata City, Japan 951-8585. Phone: 025-227-0651; Fax: 025-223-5287; E-mail: ryaman{at}bri.niigata-u.ac.jp.

Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent malignant glioma.

Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432, and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally every 3 weeks.

Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10 patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that in the control group.

Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients.

Key Words: Glioma • Dendritic Cell • Immunotherapy

This article has been cited by other articles:

				O. M. Grauer, J. W. Molling, E. Bennink, L. W. J. Toonen, R. P. M. Sutmuller, S. Nierkens, and G. J. Adema TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas J. Immunol., November 15, 2008; 181(10): 6720 - 6729. [Abstract] [Full Text] [PDF]

				K. S. Hill, F. Errington, L. P. Steele, A. Merrick, R. Morgan, P. J. Selby, N. T. Georgopoulos, D. M. O'Donnell, and A. A. Melcher OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions J. Immunol., September 1, 2008; 181(5): 3108 - 3115. [Abstract] [Full Text] [PDF]

				Z. Xiong, S. Gharagozlou, I. Vengco, W. Chen, and J. R. Ohlfest Effective CpG Immunotherapy of Breast Carcinoma Prevents but Fails to Eradicate Established Brain Metastasis Clin. Cancer Res., September 1, 2008; 14(17): 5484 - 5493. [Abstract] [Full Text] [PDF]

				C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X.-x. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin, and J. S. Yu Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients Cancer Res., July 15, 2008; 68(14): 5955 - 5964. [Abstract] [Full Text] [PDF]

				S. De Vleeschouwer, S. Fieuws, S. Rutkowski, F. Van Calenbergh, J. Van Loon, J. Goffin, R. Sciot, G. Wilms, P. Demaerel, M. Warmuth-Metz, et al. Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme Clin. Cancer Res., May 15, 2008; 14(10): 3098 - 3104. [Abstract] [Full Text] [PDF]

				G. D. King, A.K.M. G. Muhammad, J. F. Curtin, C. Barcia, M. Puntel, C. Liu, S. B. Honig, M. Candolfi, S. Mondkar, P. R. Lowenstein, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model Neuro-oncol, February 1, 2008; 10(1): 19 - 31. [Abstract] [Full Text] [PDF]

				S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al. Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells J. Immunol., October 1, 2007; 179(7): 4874 - 4883. [Abstract] [Full Text] [PDF]

				J. Haapasalo, K. Nordfors, S. Jarvela, H. Bragge, I. Rantala, A.-K. Parkkila, H. Haapasalo, and S. Parkkila Carbonic anhydrase II in the endothelium of glial tumors: A potential target for therapy Neuro-oncol, July 1, 2007; 9(3): 308 - 313. [Abstract] [Full Text] [PDF]

				S. Koido, E. Hara, S. Homma, A. Torii, M. Mitsunaga, S. Yanagisawa, Y. Toyama, H. Kawahara, M. Watanabe, S. Yoshida, et al. Streptococcal Preparation OK-432 Promotes Fusion Efficiency and Enhances Induction of Antigen-Specific CTL by Fusions of Dendritic Cells and Colorectal Cancer Cells J. Immunol., January 1, 2007; 178(1): 613 - 622. [Abstract] [Full Text] [PDF]